Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Duopharma Biotech Bhd's quarterly market cap
declined
from Sep. 2025 (RM1,269.8 Mil) to Dec. 2025 (RM1,202.4 Mil) but then
increased
from Dec. 2025 (RM1,202.4 Mil) to Mar. 2026 (RM1,221.7 Mil).
Duopharma Biotech Bhd's annual market cap
declined
from Dec. 2023 (RM1,212.0 Mil) to Dec. 2024 (RM1,202.4 Mil) but then
stayed the same
from Dec. 2024 (RM1,202.4 Mil) to Dec. 2025 (RM1,202.4 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Duopharma Biotech Bhd's Enterprise Value for Today is RM1,375.4 Mil.
Duopharma Biotech Bhd (XKLS:7148) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XKLS:7148 vs ZTS, UTHR, VTRS: Market Cap Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Duopharma Biotech Bhd's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Duopharma Biotech Bhd Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Duopharma Biotech Bhd's Market Cap distribution charts can be found below:
* The bar in red indicates where Duopharma Biotech Bhd's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Duopharma Biotech Bhd's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Duopharma Biotech Bhd (XKLS:7148) has a Market Cap of RM1,164.0 Mil as of Jul. 16, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Duopharma Biotech Bhd and its competitors. According to the industry distribution chart, Duopharma Biotech Bhd ranks #488 out of 1024 companies in the Drug Manufacturers industry, placing it in the top 47.7%.
Is Duopharma Biotech Bhd's Market Cap too high?
Duopharma Biotech Bhd's current Market Cap is RM1,164.0 Mil. Based on the distribution chart, Duopharma Biotech Bhd ranks #488 out of 1024 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Duopharma Biotech Bhd has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Duopharma Biotech Bhd's Market Cap compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Duopharma Biotech Bhd ranks #488 out of 1024 companies for Market Cap. This puts Duopharma Biotech Bhd in the upper half of its industry. The industry median Market Cap is 219.58. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 219.58, based on 1,024 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Duopharma Biotech Bhd and its competitors. For the Drug Manufacturers industry, the median Market Cap is 219.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Duopharma Biotech Bhd's current Market Cap is RM1,164.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Duopharma Biotech Bhd stock overvalued right now?
Based on GuruFocus' analysis, Duopharma Biotech Bhd (XKLS:7148) is currently considered Modestly Undervalued. The stock's GF Value™ is RM1.53, compared to a current price of RM1.21 — trading 20.9% below its estimated fair value. The current Market Cap is RM1,164.0 Mil. Duopharma Biotech Bhd's overall GF Score™ is 82/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Duopharma Biotech Bhd (XKLS:7148), the current Market Cap is RM1,164.0 Mil as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Duopharma Biotech Bhd (XKLS:7148) Overvalued in 2026?
Based on GuruFocus' analysis, Duopharma Biotech Bhd stock appears to be undervalued.
The current stock price of RM1.21 is trading 20.9% below its estimated GF Value™ of RM1.53.
GuruFocus considers Duopharma Biotech Bhd to be Modestly Undervalued.
Key valuation signals for XKLS:7148:
Market Cap: RM1,164.0 Mil
GF Value™: RM1.53 vs. price of RM1.21 (20.9% below fair value)
No single metric tells the full story. See the XKLS:7148 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Duopharma Biotech Bhd is an investment holding company engaged in manufacturing pharmaceuticals. The company develops, manufactures, and markets generic and over-the-counter pharmaceutical products. The operating segment of the company is the manufacturing and distribution of pharmaceutical products. The principal activities of its subsidiary are to carry out business as a manufacturer, distributor, importer, and exporter of pharmaceutical products and medicines. Geographically, the company generates the majority of its revenue from Malaysia.
82GF Score
Get the complete analysis for XKLS:7148
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKLS:7148 has been successfully added to your 
